Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Asset disposition Appointed CFO Quarterly results Auditor change
|
Eledon Pharmaceuticals, Inc. (NVUS)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 10% stake in Eledon Pharmaceuticals, Inc. |
02/14/2022 |
SC 13G/A
| Cormorant Asset Management, LP reports a 9.9% stake in Eledon Pharmaceuticals, Inc. |
02/11/2022 |
SC 13G/A
| Woodline Partners LP reports a 4.8% stake in Eledon Pharmaceuticals, Inc. |
02/10/2022 |
SC 13G/A
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 0% stake in Eledon Pharmaceuticals, Inc. |
02/09/2022 |
SC 13G/A
| FMR LLC reports a 3.5% stake in ELEDON PHARMACEUTICALS INC |
01/28/2022 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 16.9% stake in Eledon Pharmaceuticals, Inc. |
01/26/2022 |
SC 13G/A
| Logos Global Management LP reports a 0% stake in Eledon Pharmaceuticals, Inc. |
09/09/2021 |
SC 13G/A
| Logos Global Management LP reports a 9.4% stake in Eledon Pharmaceuticals, Inc. |
02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
12/30/2020 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 10% stake in Novus Therapeutics, Inc. |
12/28/2020 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 10% stake in Novus Therapeutics, Inc. |
10/05/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend] |
02/12/2016 |
SC 13G/A
| Tokai Pharmaceuticals Inc reports a 7.9% stake in Tokai Pharmaceuticals, Inc. |
|
|